Jamie Threatt
Acute Care · Atlanta, GANPI 1255784617
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 26.5% of the total. Reporting peaked in 2024 at $1,780 and has fallen 97.6% since, to $43 in 2025. Among acute care clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$499
- Grifols USA, LLC$308
- Takeda Pharmaceuticals U.S.A., Inc.$303
- Actelion Pharmaceuticals US, Inc.$286
- Mylan Specialty L.p.$240
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,711100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 36 | $1,251 |
| GSK | 35 | $499 |
| Grifols USA, LLC | 13 | $308 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $303 |
| Actelion Pharmaceuticals US, Inc. | 12 | $286 |
| Mylan Specialty L.p. | 12 | $240 |
| Electromed, Inc. | 17 | $221 |
| Amgen | 9 | $207 |
| Sanofi | 6 | $187 |
| Regeneron Healthcare Solutions, Inc. | 7 | $167 |
| Merck | 6 | $147 |
| Bayer | 6 | $137 |
| Insmed, Inc. | 5 | $134 |
| Boehringer Ingelheim | 7 | $128 |
| United Therapeutics Corporation | 4 | $92 |
| Vifor Pharma, Inc. | 3 | $71 |
| Baxter Healthcare | 2 | $57 |
| Johnson & Johnson(2 entities) | 2 | $53 |
| Novartis | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Inogen, Inc. | 2 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| AbbVie | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| CMP Pharma, Inc. | 1 | $12 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,727 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 50 | $689,985 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 287 | $241,717 |
| Dupixent PenDupilumab | 36 | $138,470 |
| Breo ElliptaFluticasone/Vilanterol | 120 | $53,928 |
| NucalaMepolizumab | 12 | $44,223 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $32,437 |
| EliquisApixaban | 29 | $28,276 |
| Spiriva RespimatTiotropium Bromide | 25 | $18,845 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $18,035 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $10,987 |
| Arnuity ElliptaFluticasone Furoate | 27 | $10,422 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $10,411 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $9,696 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $9,450 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $6,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $128 | $726,86498 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta | $499 | $388,734521 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,251 | $21,39751 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.
Other acute care in Atlanta
- Sarah WymanAtlanta$10K
- Ayeshia PowellAtlanta$10K
- Michael WattsAtlanta$6K
- Merry NevilleAtlanta$5K
- Annalee EdwardsAtlanta$5K
- Kenya RaglandAtlanta$4K
- Emma HallAtlanta$4K
- Gretchen HallAtlanta$4K
- Summer DaviesAtlanta$4K
- Darryl TurnerRinggold$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.